Nekonal Oncology

In February 2017, SalvaRx formed a collaboration with Nekonal SARL (“Nekonal”), a Luxembourg-based company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology.  As part of the agreement, SalvaRx and Nekonal formed a joint venture company, Nekonal Oncology Limited (“Nekonal Oncology”), that will explore  applications of Nekonal's technology in the field of cancer imunotherapy.

Nekonal Oncology will focus on the development of first-in-class antibodies against a novel T-cell based target having potential for use as a monotherapy and combination therapy for solid and haematological malignancies.  SalvaRx will oversee a work plan that will advance multiple therapeutic antibodies towards the clinic for use in oncology.